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AbstrAct
Objective To study changes on Mri of the spine and 
sacroiliac joint (siJ) in early axial spondyloarthritis (axspa) 
over time.
Methods in the Devenir des spondyloarthropathies 
indifférenciées récentes cohort, Mri- spine and Mri- siJ at 
baseline and 2 and 5 years were scored by central readers 
for bone marrow oedema (BMe), fatty lesions, erosions, 
sclerosis, ankylosis and spinal bone spurs. The average 
mean number of lesions was reported or the agreement of 
≥2 out of 3 readers for binary outcomes. net progression 
was calculated by subtracting the patients that ‘improved’ 
from those that ‘worsened’ divided by the total number of 
patients.
Results Over 5 years, in 155 patients with axspa (mean 
age 33.5 (sD 8.9) years, symptom duration 1.4 (0.8) 
years, 63% human leucocyte antigen+, 14% modified 
new York+), BMe on Mri- siJ decreased by a mean 
spondyloarthritis research consortium of canada score 
of 1.4 (sD 6.5) (p=0.009). The largest BMe decrease was 
observed in patients using biological disease- modifying 
antirheumatic drugs at 5 years. spinal BMe increased by 
0.3 (4.6) (p=0.41). Fatty lesions and/or erosions on Mri- 
siJ increased by a mean of 1.0 (sD 2.6) (p<0.001). spinal 
fatty lesions and/or erosions increased by 0.2 (sD 0.5) 
(p<0.001). compared with baseline, at 5 years, 7.3% less 
patients had BMe on Mri- siJ according to the assessment 
of spondyloarthritis international society definition, while 
6.6% more patients had ≥5 fatty lesions and/or erosions. 
at 5 years, 0.7% less patients had ≥5 spinal BMe lesions 
and 0.7% less patients had ≥5 spinal fatty lesions.
Conclusion Over 5 years, BMe on Mri- siJ decreased 
and spinal BMe remained similar, but numerically, little 
progression of structural lesions on Mri of the siJ and 
spine was seen.
InTROduCTIOn
Axial spondyloarthritis (axSpA) is a chronic 
inflammatory rheumatic disease affecting the 
axial skeleton. When definite signs of sacro-
iliitis are seen on conventional radiography, 
patients can be diagnosed with radiographical 
axSpA or ankylosing spondylitis (AS). AxSpA 
is called non- radiographical axSpA when no 
definite abnormalities can be detected on 
radiographs of the sacroiliac joint (SIJ).
MRI gained interest due to its ability to 
visualise both inflammation and structural 
changes in the axial skeleton. On MRI of 
the SIJ (MRI- SIJ), subchondral bone marrow 
oedema (BME) is thought to reflect active 
inflammation, while MRI- detectable sclerosis, 
erosions, fatty lesions, spinal bone spurs and 
sacroiliac ankylosis reflect structural damage.1
In particular, detection of BME on MRI- SIJ 
is used in diagnosis and has become part of 
the current classification criteria for axSpA.2 3 
Key messages
What is already known?
 ► Outside of clinical trials, little is known of the course 
of spondyloarthritis- associated Mri abnormalities in 
the spine and sacroiliac joints (siJs).
What does this study add?
 ► in patients in the Devenir des spondyloarthropathies 
indifférenciées récentes cohort over 5 years, bone 
marrow oedema (BMe) on Mri- siJ decreased sig-
nificantly, with the largest decrease observed in 
patients using biological disease- modifying anti-
rheumatic drugs at 5 years.
 ► BMe in the spine was uncommon but remained sim-
ilar over 5 years.
 ► in line with previous data on radiographical progres-
sion from the cohort, over 5 years, little progression 
in structural Mri lesions in spine and siJs was seen.
How might this impact on clinical practice?
 ► This suggest that in patients with early axial spon-
dyloarthritis (axspa), a repeated Mri to detect pro-
gression of structural lesions with high specificity for 
axspa in the first years of disease is of limited value.
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Given that sacroiliac BME may also occur in other condi-
tions and even in healthy individuals, assessment of struc-
tural changes in the SIJ,to enhance the diagnostic utility of 
MRI is a subject of active research.4 For example, presence 
of at least three fatty lesions or at least five fatty lesions and/
or erosions on MRI- SIJ has a reported >90% specificity 
for early axSpA. The same study showed that at least five 
inflammatory BME lesions or at least five fatty lesions on 
MRI- spine have a similarly high specificity for axSpA.56
MRI lesions may also have potential prognostic value as 
in patients with AS in clinical trials, vertebral corner BME 
is associated with subsequent radiographical progres-
sion, with one study also showing an association between 
fatty lesions and progression.7 Strikingly, while the asso-
ciation between MRI lesion and radiographical damage 
is far from clear, spinal MRI outcomes are already used 
to study the effect of treatment. For example, although 
it was acknowledged that the significance of the finding 
was unclear, the authors of a study on the 2- year effect 
of secukinumab treatment on spinal MRI findings in 
AS did believe it was worth reporting that the observed 
progression of spinal fatty lesion compared favourable 
to previous studies on tumour necrosis factor (TNF) 
blockers.8
With little known of the course of MRI abnormalities 
outside of clinical trials, we studied changes in spondy-
loarthritis (SpA)- associated inflammatory and structural 
lesions on both MRI of the SIJ and spine over 5 years in a 
cohort of patients with early disease.
MeTHOds
study population and design
Five- year follow- up data from the Devenir des Spondy-
loarthropathies Indifférenciées Récentes (DESIR) cohort 
were used. The design and inclusion criteria of this 
cohort have been previously described in detail.9 In brief, 
the DESIR cohort is a French longitudinal prospective 
multicentre cohort study established between 2007 and 
2010 that includes patients aged ≥18 and ≤50 years with 
inflammatory back pain for ≥3 months but ≤3 years and 
symptoms suggestive of axSpA according to the treating 
rheumatologist (with a level of confidence score of ≥5 on 
a 0–10 numerical rating scale in which 0=not suggestive 
and 10=very suggestive of SpA).
Of the 708 patients included, the baseline average 
confidence of diagnosis was 6.8 SD ±2.7. Ninety- two per 
cent met at least one set of SpA classification criteria: 
modified New York criteria 26%, Amor 79%, European 
Spondyloarthropathy Study Group (ESSG) 78% and 
Assessment of Spondyloarthritis International Society 
(ASAS) axSpA criteria 70%.9
The database used for the current analysis was locked 
on 20 of June 2016.
MRI assessments
MRI- SIJ and MRI- spine were performed on a 1 .0–1.5 T 
scanner providing T1- weighted (T1- w) turbo spin- echo and 
short tau inversion recovery (STIR) sequences. Coronal 
oblique plane was performed for the MRI- SIJ and sagittal 
plane for MRI- spine with a slice thickness of 4 mm.
MRI- SIJ and MRI- spine were performed at baseline for 
all patients. By protocol, at 2 and 5 years of follow- up, 
MRIs were only performed in participating centres in 
Paris. The MRIs were evaluated independently by three 
central readers. Readers were blinded for all clinical and 
laboratory data, the chronology of images and the results 
from other imaging modalities.
MRI-sIJ
Readers scored the images for presence of BME lesions 
according to the ASAS definition for a positive MRI- SIJ2 
and according to the Spondyloarthritis Research Consor-
tium of Canada (SPARCC) scoring method (range 
0–72).10 11 Fatty lesions, erosions, sclerosis and (partial) 
ankylosis are considered to be typical structural lesion 
for axSpA seen on MRI.1 The adapted SPARCC MRI- SIJ 
Structural Score by Weber et al was used for this study.12 
This method is based on MRI T1- w images, anatomical 
slice selection and dichotomous scoring (lesion present/
absent) of six consecutive slices through the cartilaginous 
part of the SIJ, divided in quadrants. Erosions and fatty 
lesions were marked as present if seen on at least two 
consecutive slices and had a scoring range of 0–40 each. 
Ankylosis or partial ankylosis was considered present if 
seen on a single slice. It is assumed that partial ankylosis 
and ankylosis cannot occur simultaneously in a quadrant, 
and ankylosis always involves two quadrants; therefore, 
the corresponding scoring range is 0–24.
In the current study, sclerosis was added to the adapted 
SPARCC MRI- SIJ structural score and was defined as low- 
intensity or signal- free bands on both the T1- w and the 
STIR sequence extending at least 5 mm from the space 
between the SIJ.1 Sclerosis was scored in a similar way as 
the erosions and fatty lesions. The scoring range for the 
total number of structural lesions was defined as 0–144 
since the number of fatty lesions, erosions, sclerosis and 
(partial) ankylosis was summed.
MRI-spIne
Twenty- three vertebral units (VUs) were scored for BME 
lesions according to the Berlin method (range 0–69)13 14 
and the spinal SPARCC (s- SPARCC) method (range 0–414), 
which is scored by quadrants per VU.11 In addition, MRI- 
spine was also dichotomously defined as positive if ante-
rior/posterior BME was present in ≥3 sites of the spine 
according to the ASAS definition.15 For further evaluation, 
a cut- off of ≥5 BME lesions was used.5 Spinal structural 
lesions seen on MRI were assessed by using the Canada–
Denmark (CANDEN) scoring method.16 All 23 VUs were 
divided into quadrants. The CANDEN scoring method 
was slightly modified; only corner lesions (erosions, fatty 
lesions, bone spurs and ankylosis) were scored. Erosions 
scores were dichotomised (present yes/no) and scored 
when present on ≥1 slice (range 0–92). Bone spurs and 
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Figure 1 Overview of follow- up MRI over 5 years (A) and 2 years (B) of either the SIJ, spine or both. Reading of T1- weighted 
sequence is present from all three readers. *One missing MRI- SIJ short tau inversion recovery sequence in MRI. SIJ, sacroiliac 
joint.
fatty lesions were scored when present on ≥1 slice (range 
0–92), and ankylosis was scored per two quadrants when 
present on ≥1 slice (range 0–46). The total number of 
structural lesions, compiled by spinal fatty lesions, erosions, 
bone spurs and ankylosis, has a range of 0–322.
For both MRI- SIJ and MRI- spine, continuous scores 
were reported as the mean number of lesions (average 
of three readers) and as the agreement of ≥2 out of 3 
readers for binary outcomes.
statistical analysis
Statistical testing was performed to compare MRI inflam-
mation and structural damage across different time 
points using paired t- test. For the binary outcomes, the 
proportion of patients with positive change (% patients 
with worsening) and negative change (% patients with 
improvement) over 5 years was determined using the cut- 
offs defined previously. The net percentage of change 
defines the number of patients with a positive change 
minus the number of patients with a negative change 
divided by the total number of patients included in the 
analysis.17 To assess reliability of continuous scores across 
the three readers, the intraclass correlation coefficients 
(ICCs) with 95% CIs were calculated, and the following 
definition for interpreting ICC values was used: <0.5, 
0.5–0.8, 0.8-0.9 and >0.9 were interpreted as respectively 
poor, moderate, good and excellent reliabilities.18
Statistical analysis was performed using STATA SE V.15.
ResulTs
Baseline characteristics
In the DESIR cohort, baseline MRIs were performed in 
614 of the 708 included patients. Of these 614 patients, 
167 were from centres which performed repeated MRIs 
at follow- up visits. Of these 167 patients, 140 had MRI 
follow- up at 2 years, and 155 had follow- up MRI at 5 years 
(figure 1A). In figure 1A, the exact number of available 
numbers of MRI reading at each time point is shown.
Baseline characteristics of the 155 patients with 
repeated MRI at 5 years were comparable with the 459 
patients with only MRIs at baseline (table 1). In the 155 
patients with complete 5- year MRI readings, 81 (52%) 
were female with a mean age of 33.5 (SD 8.9) years. 
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Table 1 Baseline characteristics of patients (N=614) in the Devenir des Spondyloarthropathies Indifférenciées Récentes 
cohort with baseline MRI reading split according to the availability of 5- year MRI imaging of the SIJ and/or spine
Patients with follow- up MRI*
(n=155)
Patients without follow- up MRI
(n=459)
Age at baseline (years) 33.5 (8.9) 33.9 (8.7)
Female gender, n (%) 81/155 (52) 248/459 (54)
Symptom duration (years) 1.4 (0.8) 1.6 (0.9)†
Peripheral arthritis, n (%) 36/153 (24) 103/459 (22)
Uveitis, n (%) 12/155 (7.7) 45/459 (10)
Enthesitis, n (%) 91/155 (59) 258/459 (56)
Dactylitis, n (%) 22/155 (14) 64/458 (14)
IBD, n (%) 8/155 (5.2) 25/459 (6)
Psoriasis, n (%) 30/155 (19) 77/459 (17)
Good response to NSAIDs, n (%) 136/155 (88) 397/455 (87)
Positive family history, n (%) 64/145 (44) 191/435 (44)
HLA- B27 positive, n (%) 98/155 (63) 269/458 (59)
Elevated CRP (≥6 mg/L), n (%) 41/148 (28) 133/445 (30)
Radiographical sacroiliitis baseline (mNY), n (%) 21/150 (14) 65/446 (15)
Meeting the ASAS axSpA criteria 102/154 (66%) 276/448 (62%)
ASDAS- CRP† 2.7 (0.9) 2.6 (1.0)
BASFI† (0–10) 3.1 (2.4) 3.0 (2.2)
Use of NSAIDs, n (%) 147/155 (95) 424/459 (92)
Use of bDMARDs at baseline, n (%) 0/155 (0) 0/459 (0)
All numbers in the table are mean (SD) unless indicated otherwise.
*Patients with both baseline and 5- year MRI available of either the SIJ, spine or both.
†<5% missing data.
ASAS, Assessment of Spondyloarthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial 
spondyloarthritis; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biological disease- modifying antirheumatic drug; CRP, C 
reactive protein; HLA- B27, human leucocyte antigen; IBD, inflammatory bowel disease; mNY, modified New York; NSAID, non- steroidal anti- 
inflammatory drug; SIJ, sacroiliac joint.
The mean symptom duration at baseline was 1.4 (SD 
0.8) years, and 98 (63%) were human leucocyte antigen 
B27 positive. Sixty- six per cent of patients met the ASAS 
classification criteria, and none of the patients were 
using biological disease- modifying antirheumatic drugs 
(bDMARDs) at baseline.
Reliability of MRI scores
Overall, the ICCs for status scores and mean change of 
sacroiliac BME were good: baseline, 0.9 (95% CI 0.8 to 
0.9); 2 years, 0.9 (95% CI 0.8 to 0.9); 5 years, 0.8 (95% CI 
0.7 to 0.9); and 5- year mean change: 0.8 (95% CI 0.8 to 
0.9). The ICCs for spinal BME were moderate and similar 
over the scoring methods: baseline Berlin, 0.7 (95% CI 
0.6 to 0.8); baseline SPARCC, 0.7 (95% CI 0.6 to 0.8); 
2- year Berlin, 0.6 (95% CI 0.5 to 0.7); 2- year SPARCC, 
0.6 (95% CI 0.6 to 0.7); 5- year Berlin, 0.6 (95% CI 0.5 to 
0.6); 5- year SPARCC, 0.6 (95% CI 0.5 to 0.6); 5- year mean 
change Berlin, 0.6 (95% CI 0.5 to 0.7); and 5- year mean 
change SPARCC, 0.6 (95% CI 0.6 to 0.7).
In the supplementary data, the individual reader scores 
of both sacroiliac (online supplementary table S1) and 
spinal structural lesions (including spinal bone spurs) 
(online supplementary table S2) are presented in detail 
with corresponding ICC values. The overall ICCs for 
status scores for sacroiliac structural lesions on MRI were 
moderate (erosions) to good (fatty lesions and lesions 
combined) at 2 and 5 years (range 0.5–0.9). The ICCs of 
mean change scores for sacroiliac structural lesions over 
5 years were poor (erosions) to moderate (fatty lesion 
and lesions combined) (range 0.3–0.6). Status scores 
for spinal lesions on MRI had poor (erosions, bone 
spurs, to moderate (fatty lesions and lesions combined) 
ICC values (range 0.0–0.7); ICCs of the different spinal 
change scores were poor (range 0.0–0.3).
Change in MRI-sIJ lesions over 5 years of follow-up
Table 2 presents the status scores with the mean change 
over time for sacroiliac BME and structural lesions at 
baseline and at 2 and 5 years. Over 5 years, a decrease in 
mean SPARCC score of −1.4 (SD 6.5) (p=0.009, baseline 
vs 5 years) was observed. After 5 years the percentage of 
patients meeting the ASAS definition of a positive MRI 
had decreased by 7.3% from 29.3% to 22.0%.
Over 5 years (ie, comparing the 5- year score with the 
baseline score), the mean number of erosions on MRI- SIJ 
increased by 0.2 (SD 1.4) (p=0.085); the mean number of 
fatty lesions increased by 0.8 (SD 2.2) (p<0.001); and the 
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Table 2 BME and structural lesions on MRI- sacroiliac joint of patients from the Devenir des Spondyloarthropathies 
Indifférenciées Récentes cohort over 5 years of follow- up
Baseline 
mean (SD) 
(n=150)*
2 years’ 
mean (SD) 
(n=136)
5 years’ 
mean (SD) 
(n=150)*
Change over 5 years’ 
mean (SD) P value†
BME lesions (scores)
Mean SPARCC score‡ (0–72)   3.8 (7.2) 2.8 (5.8) 2.4 (4.7) −1.4 (6.5) 0.009
Structural lesions (scores)
Mean number of erosions‡ (0–40) 1.0 (1.9) 1.1 (2.0) 1.2 (2.1) 0.2 (1.4) 0.085
Mean number of fatty lesions‡
(0–40)
  1.1 (2.6) 1.7 (4.0) 1.9 (4.1) 0.8 (2.2) <0.001
Mean number of fatty lesions and/or 
erosions‡
(0–80)
  2.1 (3.9) 2.8 (5.0) 3.1 (5.1) 1.0 (2.6) <0.001
Mean total number of lesions‡§
(0–144)
  2.6 (4.5) 3.3 (6.2) 3.9 (6.5) 1.3 (3.1) <0.001
 
Baseline
n (%)
(n=150)*
2 years
n (%) 
(n=136)
5 years
n (%)
(n=150)*
Positive 
change over 
5 years
n (%)
Negative 
change 
over 5 
years
n (%)
Net change
n (%)
BME lesions (cut- off)
ASAS definition* 44 (29.3) 30 (22.1) 32 (22.0) 10 (6.7) 21 (14.0) −11 (−7.3)
 
Baseline
n (%)
2 years
n (%) 
(n=136)
5 years
n (%)
Positive 
change over 
5 years
n (%)
Negative 
change 
over 5 
years
n (%)
Net change
n (%)
Structural lesions (cut- offs)
≥3 erosions¶ 20 (13.3) 21 (15.4) 21 (13.9) 8 (5.3) 7 (4.6) 1 (0.7)
≥3 fatty lesions¶ 20 (13.3) 26 (19.1) 32 (21.2) 12 (8.0) 0 (0.0) 12 (8.0)
≥5 fatty lesions and/or erosions¶ 23 (15.2) 32 (23.5) 33 (21.9) 12 (8.0) 2 (1.3) 10 (6.6)
*Missing MRI short tau inversion recovery sequence in one case at 5 years.
†Paired samples t- test comparing baseline versus 5 years.
‡Mean of three readers.
§Fatty lesions, erosions, sclerosis and partial ankylosis/total ankylosis.
¶Agreement of ≥2 out of 3 readers.
ASAS, Assessment of Spondyloarthritis International Society; BME, bone marrow oedema; SPARCC, Spondyloarthritis Research Consortium 
of Canada.
mean number of fatty lesions and/or erosions increased 
by 1.0 (SD 2.6) (p<0.001). Sacroiliac sclerosis and 
(partial) ankylosis were rare at both baseline and 5 years 
(data not shown) and contributed little to the observed 
mean increase in the total number of structural lesions of 
1.3 (SD 3.1) (p<0.001).
Over 5 years, the net increase to ≥3 erosions was 0.7%; 
the net increase to ≥3 fatty lesions was 8.0%; and the net 
increase to ≥5 fatty lesions and/or erosions was 6.6%.
Changes in MRI-spine lesions over 5 years of follow-up
Table 3 presents the status scores with the mean change 
over time for spinal BME and structural lesions at base-
line and at 2 and 5 years. Over 5 years, non- significant 
increases in the mean Berlin score of 0.1 (SD 1.7) 
(p=0.43) and in the s- SPARCC score of 0.3 (SD 4.6) 
(p=0.41) were observed. After 5 years, the percentage of 
patients meeting the ASAS definition of a positive MRI- 
spine (≥3 BME lesions) had increased by 2.8% from 
4.8% to 7.6%, and the percentage of patients with at 
least five BME lesions had decreased by 0.7% from 3.4% 
to 2.8%.
Over 5 years, the mean number of erosions remained 
0.0 (SD 0.2) (p=1.0); the mean number of bone spurs 
increased by 0.1 (SD 0.3) (p=0.012); the mean number 
of fatty lesions increased by 0.1 (SD 0.4) (p=0.001); the 
mean number of fatty lesions and/or erosions increased 
by 0.2 (SD 0.5) (p<0.001); and the mean total number 
of structural lesions increased by 0.2 (SD 0.6) (p<0.001). 
Spinal sclerosis and ankylosis were rare at both baseline 
and 5 years (data not shown).
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Table 3 BME and structural lesions on MRI- spine of patients from the Devenir des Spondyloarthropathies Indifférenciées 
Récentes cohort over 5 years of follow- up
Baseline mean 
(SD) (n=145)
2 years’ 
mean (SD) 
(n=129)
5 years’ 
mean (SD) 
(n=145)
Change over 5 years 
mean (SD) P value*
BME lesions (scores)
Mean Berlin score† (0–69) 0.6 (1.5) 0.6 (1.2) 0.7 (1.3) 0.1 (1.7) 0.43
Mean 23 DVU SPARCC score† (0–414) 1.6 (4.1) 1.7 (3.3) 1.9 (3.7) 0.3 (4.6) 0.41
Structural lesions (scores)
Mean number of erosions†‡ (0–92) 0.1 (0.2) 0.1 (0.2) 0.1 (0.2) 0.0 (0.2) 1.000
Mean number of bone spur†‡ (0–92) 0.1 (0.3) 0.2 (0.3) 0.2 (0.4) 0.1 (0.3) 0.012
Mean number of fatty lesions†‡ (0–92) 0.2 (0.7) 0.3 (0.8) 0.4 (1.0) 0.1 (0.4) 0.001
Mean number of fatty lesions
and / or erosions (0–184) †‡
0.3 (0.8) 0.3 (1.0) 0.4 (1.1) 0.2 (0.5) <0.001
Mean total number of lesions§†‡ (0–322) 0.4 (0.9) 0.5 (1.1) 0.6 (1.2) 0.2 (0.6) <0.001
DVU, discovertebral unit.
 
Baseline
n (%)
(n=145)
2 years
n (%) (n=129)
5 years
n (%)
(n=145)
Positive 
change over 
5 years
n (%)
Negative 
change over 
5 years
n (%)
Net change
n (%)
BME lesions (cut- off)
ASAS ≥3 BME lesions¶ 7 (4.8) 9 (7.0) 11 (7.6) 7 (4.8) 3 (2.1) 4 (2.8)
≥5 BME lesions¶ 5 (3.4) 3 (2.3) 4 (2.8) 3 (2.1) 4 (2.8) −1 (−0.7)
 
Baseline
n (%) (n=145)
2 years
n (%) (n=129)
5 years
n (%) 
(n=145)
Positive 
change over 
5 years
n (%)
Negative 
change over 
5 years
n (%)
Net change
n (%)
Structural lesions (cut- offs)
≥3 erosions¶ 0 (0.0) 0 (0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
≥3 bone spurs¶ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
≥3 fatty lesions¶ 1 (0.7) 2 (1.6) 2 (1.4) 1 (0.7) 0 (0.0) 1 (0.7)
≥5 fatty lesions¶ 2 (1.4) 1 (0.8) 1 (0.7) 0 (0.0) 1 (0.7) −1 (−0.7)
≥5 fatty lesions and/or erosions¶ 2 (1.4) 1 (0.8) 1 (0.7) 0 (0.0) 1 (0.7) −1 (−0.7)
*Paired samples t- test comparing baseline versus 5 years.
†Mean of three readers.
‡Missing data from at least one time point and one reader for four cases.
§Fatty lesions, erosions, bone spurs and ankylosis.
¶Agreement of ≥2 out of 3 readers.
ASAS, Assessment of Spondyloarthritis International Society; BME, bone marrow oedema; SPARCC, Spondyloarthritis Research Consortium 
of Canada.
Over 5 years, the net progression to ≥5 fatty lesions on 
MRI- spine was −0.7%.
MRI changes in patients using bdMARds at 5 years
At 5 years, information on bDMARD (all TNF blockers) 
usage was available for 145 out of 155 patients with 
MRI follow- up. At 5 years, 68 of 145 patients were using 
bDMARDs and 77/145 were not.
Baseline SIJ BMEs were similar (mean SPARCC 3.7 
(SD 7.5) vs 3.5 (SD 7.5)), while at 5 years, SIJ BME was 
lower in patients using bDMARD (mean SPARCC 1.2 
(SD 2.3) vs 3.2 (SD 5.8) (p=0.01 comparing bDMARD 
vs non- bDMARD users at 5 years)). In all patients, over 
5 years, no significant change in spinal BME was seen 
(mean Berlin 0.1 (SD 1.7) and mean 23 DVU SPARCC 
0.3 (SD 4.6)) (table 3). After subdividing these groups 
in to bDMARD users versus non- users, a similar pattern 
was seen between the two groups: bDMARD users’ mean 
Berlin was 0.1 and mean 23 DVU SPARCC 0.4 and non 
bDMARD users Berlin 0.1 and mean 23 DVU SPARCC 0.3 
with all changes not statistically significant.
At both baseline and 5 years, the mean total number 
of structural lesions in both SIJ and spine was similar in 
patients using bDMARDs and not using bDMARDs (SIJ 
baseline 2.9 (SD 5.5) vs 2.6 (SD 5.4), SIJ 5 years 3.8 (SD 
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7.9) vs 4.2 (SD 7.8), spine baseline 0.5 (SD 1.2) vs 0.4 (SD 
0.9); spine 5 years 1.9 (SD 4.4) vs 2.3 (SD 4.4)).
dIsCussIOn
Over 5 years, BME on MRI- SIJ decreased and structural 
lesions on MRI- SIJ increased significantly in patients with 
early axSpA . The increase in structural lesions was mostly 
due to fatty lesions, which led to a small increase in the 
number of patients with a number of structural lesions 
with a high specificity for axSpA (ie, ≥5 fatty lesions and/
or erosions).
In addition, spinal BME remained essentially 
unchanged, and a statistically significant but (in absolute 
numbers) very small increase in total spinal structural 
lesions was observed.
However, the number of patients with a number of struc-
tural lesions highly specific for axSpA (ie, ≥5 fatty lesions) 
also remained low on MRI- spine over time. These results 
are consistent with previously reported limited radiograph-
ical progression in patients from this cohort.17 19
To our knowledge, these are the first long- term MRI 
data from an early disease inception cohort. The MRI- SIJ 
results are consistent with data from clinical trials where, 
in particular, an increase in fatty lesions was mirrored 
by a decrease in BME over time.20 21 However, signifi-
cant changes in erosions on MRI- SIJ were not observed 
in the DESIR cohort. This partly contrasts with previous 
findings from a clinical trial where regression of sacro-
iliac erosions was reported after initiation of bDMARD 
therapy. However, patients in this trial had much higher 
baseline levels of erosions than in our cohort, and strik-
ingly, the decrease in MRI erosions was found using the 
SPARCC method and not the Berlin method.20
As patients using a bDMARD showed the largest decrease 
in SIJ and spinal BME over 5 years, it is likely that these MRI 
changes were indeed caused by treatment. However, this 
requires further investigation, specifically designed for this 
aim, and will be addressed in future analyses (including 
taking into account, for instance, confounding by indica-
tion). This may have implications for clinical practice. As 
there is no single feature on imaging that discriminates 
between axSpA and other conditions characterised by 
chronic back pain, a diagnosis of early axSpA can be chal-
lenging and diagnostic uncertainty is a common problem. 
This is particularly true for patients suspected of axSpA 
already receiving TNF blockers (for instance, because of 
inflammatory bowel disease or uveitis), where it is diffi-
cult to know if SIJ BME would have been present if the 
patient would not have used medication. Moreover, as in 
the current study, in early disease, the number of patients 
with net progression to structural lesions with a high spec-
ificity for axSpA was limited; diagnostic sensitivity of struc-
tural lesions on MRI remained low. Therefore, a repeated 
MRI in cases of diagnostic uncertainty in the first 5 years 
of disease to detect progression to a number of structural 
lesions highly specific (i.e. ≥5 fatty lesions and/or erosions) 
for axSpA is likely to be of limited value.21
Although sometimes useful to rule out other causes of 
back pain in patients suspected of axSpA, spinal MRI is 
not routinely used in diagnosis of the disease.6 The low 
percentage of patients having spinal lesions with a high 
specificity for axSpA at both baseline and over 5 years 
supports this practice. Overall, the number of both spinal 
and sacroiliac MRI lesions was lower in our patients with 
early disease compared with patients included in clinical 
trials with active disease (with the possible exception of 
structural lesions in patients with exclusively recent onset 
of non- radiographical axSpA).22
This is relevant not only when interpreting trial data 
but also when designing clinical trials and, in particular, 
for trials where longitudinal detection of changes on 
MRI imaging are relevant outcomes.
A strength of this study is the longitudinal analysis of 
MRI data from an inception cohort and thus gaining 
insight in the early phase of axSpA on MRI. In addition, 
evaluation of structural lesions on MRI was done using 
multiple readers. However, a clear limitation is the low 
prevalence of some MRI lesions (eg, bone spurs or spinal 
erosions) contributing to low ICC values, which made the 
interpretation of the reliability for these lesions difficult.13
Moreover, it is important to emphasise that the patients 
in this cohort study are more heterogenous than clinical 
trials patients. For example, meeting the ASAS classifi-
cation criteria was not a requirement for inclusion and 
treatment was not standardised. Finally, although baseline 
characteristics were similar, follow- up MRI was performed 
in only a limited number of patients in the cohort, that is, 
in the centres that were part of a group of hospitals in Paris.
Nevertheless, for future studies, these longitudinal data 
provide the opportunity to study correlations between 
spinal and sacroiliac BME and subsequent development 
of structural lesions over time. This may not only present 
useful prognostic information but may also help in 
understanding the pathophysiology of axial SpA.
In conclusion, in our cohort in the first 5 years, sacro-
iliac BME decreased and structural lesions increased 
significantly in the SIJ. Spinal BME remained similar and 
structural progression was minimal. The percentage of 
patients with a net change was low for all active and struc-
tural lesions on MRI- SIJ and MRI- spine.
Thus, given the low progression to a number of lesions 
with high specificity for axSpA, performing a repeated 
MRI to detect progression of structural lesions in the first 
5 years of early axSpA is likely to be of limited value, but 
these data may be used to study the relationship between 
SpA- associated MRI abnormalities, including the effect of 
treatment.
Author affiliations
1Department of rheumatology, leiden University Medical center, leiden, the 
netherlands
2nOVa Medical school, Universidade nova de lisboa, lisbon, Portugal
3Department of rheumatology, cochin hospital, assistance Publique- hôpitaux de 
Paris, Paris, France
4Department of rheumatology, henri Mondor hospital, aPhP, and Université Paris 
est créteil, ea, 7379 - epiderme, F-94010, créteil, France
Protected by copyright.
 o
n
 February 18, 2020 at UNL/Fac Ciencias M
edicas Biblioteca.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001093 on 5 February 2020. Downloaded from
 
8 Madari Q, et al. RMD Open 2020;6:e001093. doi:10.1136/rmdopen-2019-001093
RMD Open
5Department of rheumatology, chrU de BesancOn, University Teaching hospital, 
and Université de Franche- comté, ea4266 ePilaB, F-25030, Besançon, France
6Paris Descartes University, Paris, France
Acknowledgements The Desir cohort is conducted under the umbrella of 
the French society of rheumatology and institut national de la santé et de 
la recherche Médicale. The database management is performed within the 
department of epidemiology and biostatistics (Professor Paul landais, DiM., 
nîmes, France). The authors thank the different regional participating centers: Pr 
Maxime Dougados (Paris, cochin B), Pr andré Kahan (Paris, cochin a), Pr Olivier 
Meyer (Paris, Bichat), Pr Pierre Bourgeois (Paris, la Pitié salpetrière), Pr Francis 
Berenbaum (Paris, saint antoine), Pr Pascal claudepierre (créteil), Pr Maxime 
Breban (Boulogne Billancourt), Dr Bernadette saint- Marcoux (aulnay- sous- Bois), 
Pr Philippe goupille (Tours), Pr Jean- Francis Maillefert (Dijon), Dr Xavier Puéchal, 
Dr emmanuel Dernis (le Mans), Pr Daniel Wendling (Besançon), Pr Bernard combe 
(Montpellier), Pr liana euller- Ziegler (nice), Pr Philippe Orcel, Dr Pascal richette 
(Paris - lariboisière), Pr Pierre lafforgue (Marseille), Dr Patrick Boumier (amiens), 
Pr Jean- Michel ristori, Pr Martin soubrier (clermont- Ferrand), Dr nadia Mehsen 
(Bordeaux), Pr Damien loeuille (nancy), Pr rené-Marc Flipo (lille), Pr alain saraux 
(Brest), Pr corinne Miceli (le Kremlin Bicêtre), Pr alain cantagrel (Toulouse) and Pr 
Olivier Vittecoq (rouen). The authors also thank Unité de recherche clinique centre 
d'investigation clinic centre Paris for the coordination and monitoring of the study.
Contributors QM, as and sr performed the statistical analyses. QM and Favg 
wrote the first draft of the manuscript. all authors critically interpreted the results, 
reviewed the draft version and approved the final manuscript.
Funding Devenir des spondyloarthropathies indifférenciées récentes (Desir) 
is financially supported by an unrestricted grant from Pfizer. as is supported 
by a doctoral grant from 'Fundação para a ciência e Tecnologia' (sFrh/
BD/108246/2015). The Desir study is conducted as a Programme hospitalier de 
recherche clinique with assistance Publique hopitaux de Paris as the sponsor. The 
Desir study is also under the umbrella of the French society of rheumatology, 
which financially supports the cohort. an unrestricted grant from Pfizer has been 
allocated for the first 10 years.
Competing interests none declared.
patient consent for publication not required.
ethics approval The study was reviewed and approved by the ethical committee 
of the cochin hospital Paris, France, 75014 plus each individual study centre. 
The study was conducted according to good clinical practice guidelines Before 
inclusion, written informed consent was obtained from all participating patients.
provenance and peer review not commissioned; externally peer reviewed.
data availability statement Data are available upon reasonable request. More 
information on the Desir cohort can be found at http://www. lacohortedesir. fr/
Open access This is an open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY- nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. see: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCId ids
alexandre sepriano http:// orcid. org/ 0000- 0003- 1954- 0229
anna Molto http:// orcid. org/ 0000- 0003- 2246- 1986
Daniel Wendling http:// orcid. org/ 0000- 0002- 4687- 5780
Desirée van der heijde http:// orcid. org/ 0000- 0002- 5781- 158X
Floris a van gaalen http:// orcid. org/ 0000- 0001- 8448- 7407
RefeRences
 1 Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of 
spondyloarthritis International Society (ASAS) Handbook: a guide to 
assess spondyloarthritis. Ann Rheum Dis 2009;68 Suppl 2:ii1–44.
 2 Rudwaleit M, Jurik AG, Hermann K- GA, et al. Defining active 
sacroiliitis on magnetic resonance imaging (MRI) for classification 
of axial spondyloarthritis: a consensual approach by the ASAS/
OMERACT MRI group. Ann Rheum Dis 2009;68:1520–7.
 3 Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose 
axial spondyloarthritis early. Ann Rheum Dis 2004;63:535–43.
 4 de Winter J, de Hooge M, van de Sande M, et al. Magnetic 
resonance imaging of the Sacroiliac joints indicating sacroiliitis 
according to the assessment of spondyloarthritis International 
Society definition in healthy individuals, runners, and women with 
postpartum back pain. Arthritis Rheumatol 2018;70:1042–8.
 5 de Hooge M, van den Berg R, Navarro- Compán V, et al. Patients 
with chronic back pain of short duration from the space cohort: 
which MRI structural lesions in the sacroiliac joints and inflammatory 
and structural lesions in the spine are most specific for axial 
spondyloarthritis? Ann Rheum Dis 2016;75:1308–14.
 6 Ez- Zaitouni Z, Bakker PA, van Lunteren M, et al. The yield of 
a positive MRI of the spine as imaging criterion in the ASAS 
classification criteria for axial spondyloarthritis: results from the 
space and DESIR cohorts. Ann Rheum Dis 2017;76:1731–6.
 7 van der Heijde D, Machado P, Braun J, et al. Mri inflammation at 
the vertebral unit only marginally predicts new syndesmophyte 
formation: a multilevel analysis in patients with ankylosing 
spondylitis. Ann Rheum Dis 2012;71:369–73.
 8 Baraliakos X, Borah B, Braun J, et al. Long- Term effects of 
secukinumab on MRI findings in relation to clinical efficacy in 
subjects with active ankylosing spondylitis: an observational study. 
Ann Rheum Dis 2016;75:408–12.
 9 Dougados M, Etcheto A, Molto A, et al. Clinical presentation of 
patients suffering from recent onset chronic inflammatory back pain 
suggestive of spondyloarthritis: the DESIR cohort. Joint Bone Spine 
2015;82:345–51.
 10 Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis 
research Consortium of Canada magnetic resonance imaging 
index for assessment of sacroiliac joint inflammation in ankylosing 
spondylitis. Arthritis Rheum 2005;53:703–9.
 11 Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis 
research Consortium of Canada magnetic resonance imaging index 
for assessment of spinal inflammation in ankylosing spondylitis. 
Arthritis Rheum 2005;53:502–9.
 12 Weber U, Lambert RGW, Østergaard M, et al. The diagnostic utility 
of magnetic resonance imaging in spondylarthritis: an international 
multicenter evaluation of one hundred eighty- seven subjects. 
Arthritis Rheum 2010;62:3048–58.
 13 Lukas C, Braun J, van der Heijde D, et al. Scoring inflammatory 
activity of the spine by magnetic resonance imaging in ankylosing 
spondylitis: a multireader experiment. J Rheumatol 2007;34:862–70.
 14 Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging 
examinations of the spine in patients with ankylosing spondylitis, 
before and after successful therapy with infliximab: evaluation of a 
new scoring system. Arthritis Rheum 2003;48:1126–36.
 15 Hermann K- GA, Baraliakos X, van der Heijde DMFM, et al. 
Descriptions of spinal MRI lesions and definition of a positive MRI 
of the spine in axial spondyloarthritis: a consensual approach 
by the ASAS/OMERACT MRI study Group. Ann Rheum Dis 
2012;71:1278–88.
 16 Østergaard Met al. Structural lesions detected by magnetic 
resonance imaging in the spine of patients with spondyloarthritis 
– definitions, assessment system, and reference image set. J 
Rheumatol 2009;84:18–34.
 17 Dougados M, Sepriano A, Molto A, et al. Sacroiliac radiographic 
progression in recent onset axial spondyloarthritis: the 5- year data of 
the DESIR cohort. Ann Rheum Dis 2017;76:1823–8.
 18 Koo TK, Li MY. A guideline of selecting and reporting intraclass 
correlation coefficients for reliability research. J Chiropr Med 
2016;15:155–63.
 19 Ramiro S, van der Heijde D, Sepriano A, et al. Spinal radiographic 
progression in early axial spondyloarthritis: five- year results from the 
DESIR cohort. Arthritis care & research 2018.
 20 Pedersen SJ, Poddubnyy D, Sørensen IJ, et al. Course of magnetic 
resonance Imaging- Detected inflammation and structural lesions 
in the Sacroiliac joints of patients in the randomized, double- blind, 
placebo- controlled Danish multicenter study of adalimumab in 
spondyloarthritis, as assessed by the Berlin and spondyloarthritis 
research Consortium of Canada methods. Arthritis Rheumatol 
2016;68:418–29.
 21 Bakker PA, Ramiro S, Ez- Zaitouni Z, et al. Is it useful to repeat 
MRI of the sacroiliac joints after three months or one year in the 
diagnostic process of patients with chronic back pain suspected of 
axial spondyloarthritis? Arthritis Rheumatol 2018.
 22 Maksymowych WP, Wichuk S, Dougados M, et al. Modification of 
structural lesions on MRI of the sacroiliac joints by etanercept in 
the EMBARK trial: a 12- week randomised placebo- controlled trial in 
patients with non- radiographic axial spondyloarthritis. Ann Rheum 
Dis 2018;77:78–84.
Protected by copyright.
 o
n
 February 18, 2020 at UNL/Fac Ciencias M
edicas Biblioteca.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001093 on 5 February 2020. Downloaded from
 
